<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Tapan Ray</title>
	<atom:link href="http://www.tapanray.in/author/admin/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>From Punch Cards to Autonomous Care: India Pharma’s 50-Year Technology Journey Is Rewriting the Future of Healthcare</title>
		<link>http://www.tapanray.in/from-punch-cards-to-autonomous-care-india-pharmas-50-year-technology-journey-is-rewriting-the-future-of-healthcare/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-punch-cards-to-autonomous-care-india-pharmas-50-year-technology-journey-is-rewriting-the-future-of-healthcare</link>
		<comments>http://www.tapanray.in/from-punch-cards-to-autonomous-care-india-pharmas-50-year-technology-journey-is-rewriting-the-future-of-healthcare/#comments</comments>
		<pubDate>Sun, 22 Mar 2026 10:59:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11025</guid>
		<description><![CDATA[Executive Insight:  Over the past five decades, the Indian pharmaceutical industry has undergone a transformation that extends far beyond growth in size or global reach. It has transitioned from paper-bound, data-scarce operations reliant on centralized mainframes to a digitally integrated &#8230; <a href="http://www.tapanray.in/from-punch-cards-to-autonomous-care-india-pharmas-50-year-technology-journey-is-rewriting-the-future-of-healthcare/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-punch-cards-to-autonomous-care-india-pharmas-50-year-technology-journey-is-rewriting-the-future-of-healthcare/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>From Pharmacy of the World to AI Powerhouse? How Agentic AI Could Make or Break &#8211; India’s Pharma Future</title>
		<link>http://www.tapanray.in/from-pharmacy-of-the-world-to-ai-powerhouse-how-agentic-ai-could-make-or-break-indias-pharma-future/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-pharmacy-of-the-world-to-ai-powerhouse-how-agentic-ai-could-make-or-break-indias-pharma-future</link>
		<comments>http://www.tapanray.in/from-pharmacy-of-the-world-to-ai-powerhouse-how-agentic-ai-could-make-or-break-indias-pharma-future/#comments</comments>
		<pubDate>Sun, 15 Mar 2026 11:17:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11022</guid>
		<description><![CDATA[Executive Summary: Artificial Intelligence in pharma is undergoing a decisive transition — from Generative AI (GenAI) that produces outputs on demand to Agentic AI that can autonomously plan, decide, execute, and optimize complex workflows. For India — the world’s largest supplier of generic medicines &#8230; <a href="http://www.tapanray.in/from-pharmacy-of-the-world-to-ai-powerhouse-how-agentic-ai-could-make-or-break-indias-pharma-future/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-pharmacy-of-the-world-to-ai-powerhouse-how-agentic-ai-could-make-or-break-indias-pharma-future/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharma’s Real Marketing Bottleneck Is Not Talent &#8211; It Is Trust: Why Gen X Must Be Given Strategic Control</title>
		<link>http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control</link>
		<comments>http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/#comments</comments>
		<pubDate>Tue, 06 Jan 2026 11:34:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bottleneck]]></category>
		<category><![CDATA[Gen X]]></category>
		<category><![CDATA[Gen Y]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Talen]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11017</guid>
		<description><![CDATA[Over-managed Gen X marketers, over-relied-upon experience, and why Indian pharma’s marketing speed problem is self-inflicted. Executive Summary: The purpose of this article is to provoke a necessary leadership rethink within Indian pharmaceutical marketing. Indian pharma is not short of talent; &#8230; <a href="http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmas-real-marketing-bottleneck-is-not-talent-it-is-trust-why-gen-x-must-be-given-strategic-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why India Encourages Healthcare Innovation &#8211; but Refuses to Copy the Western IP Model</title>
		<link>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model</link>
		<comments>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/#comments</comments>
		<pubDate>Sun, 21 Dec 2025 10:43:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[exclusion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[incision]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[logic]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[orthodoxy]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[western]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11013</guid>
		<description><![CDATA[Debates on pharmaceutical innovation often polarize quickly into pro-IP and anti-IP camps. This article deliberately avoids that binary. It examines why India encourages innovation while resisting blind replication of Western IP frameworks—and why that distinction matters for healthcare outcomes. Innovation &#8230; <a href="http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-india-encourages-healthcare-innovation-but-refuses-to-copy-the-western-ip-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Data Exclusivity in India: Innovation Catalyst or Affordability Risk for Indian Pharma?</title>
		<link>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma</link>
		<comments>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 06 Dec 2025 14:33:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11008</guid>
		<description><![CDATA[For over four decades, India’s pharmaceutical industry has been built on a powerful moral and economic proposition: that life-saving medicines should be affordable, accessible, and globally available from Indian manufacturing prowess. This principle transformed India into the “pharmacy of the developing &#8230; <a href="http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-data-exclusivity-in-india-innovation-catalyst-or-affordability-risk-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India’s Healthcare Is Still Not Patient-Friendly &#8211; Why ‘Patient Centricity’ in Pharma Remains a Slogan More Than a System</title>
		<link>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system</link>
		<comments>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/#comments</comments>
		<pubDate>Sun, 23 Nov 2025 14:17:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[friendly]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[not patient]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[slogan]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11004</guid>
		<description><![CDATA[Executive Summary: Despite constant advocacy around “patient centricity,” India’s healthcare ecosystem &#8211; from pharma to hospitals &#8211; continues to show deep structural gaps. Safety failures, unethical marketing practices, opaque pricing, and hospital-level exploitation still undermine patient trust. This article uses illustrative &#8230; <a href="http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-healthcare-is-still-not-patient-friendly-why-patient-centricity-in-pharma-remains-a-slogan-more-than-a-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>In the Age of AI, Why Emotional Intelligence Is the New Competitive Edge in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sun, 16 Nov 2025 06:32:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11000</guid>
		<description><![CDATA[In today’s AI-driven world — where scientific excellence, product claims, and competitive pricing are no longer enough to differentiate pharmaceutical companies — Emotional Intelligence (EI) is rapidly emerging as the new strategic advantage in Indian pharma marketing. As doctors face shrinking time, patients demand &#8230; <a href="http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US Biosimilar Overhaul: A Breakthrough Moment or a Strategic Test for Indian Pharma</title>
		<link>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma</link>
		<comments>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/#comments</comments>
		<pubDate>Sun, 09 Nov 2025 08:01:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Breakthrough]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[overhaul]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[test]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10996</guid>
		<description><![CDATA[On 31 October 2025, the Economic Times (ET) headline— “US biosimilar norms to keep local drug cos in good health” - quickly became one of the most discussed topics across India’s biopharmaceutical circles. For India, which is transitioning from a global generics’ powerhouse &#8230; <a href="http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/us-biosimilar-overhaul-a-breakthrough-moment-or-a-strategic-test-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond the Business Card: What Retirement Truly Gives Back</title>
		<link>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-business-card-what-retirement-truly-gives-back</link>
		<comments>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/#comments</comments>
		<pubDate>Sun, 26 Oct 2025 07:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Card]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[p0wer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10986</guid>
		<description><![CDATA[A thought-provoking LinkedIn post by a highly accomplished veteran of the pharmaceutical industry — long retired, but still as insightful as ever — recently caught my attention. It sparked a series of reflections on an issue that deeply resonates with &#8230; <a href="http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
